以岭药业：中药新药“芪龙定喘片”药物临床试验申请获得受理

Core Viewpoint - Yiling Pharmaceutical has received approval from the National Medical Products Administration for a new drug clinical trial of "Qilong Dingchuan Tablets," aimed at treating chronic obstructive pulmonary disease (COPD) [1] Group 1 - The drug "Qilong Dingchuan Tablets" is intended to benefit patients by invigorating qi, promoting blood circulation, resolving phlegm, and alleviating cough and asthma [1] - The proposed indications for the drug include treatment during the stable phase of COPD, specifically for patients with qi deficiency and phlegm-stasis syndrome [1] - Symptoms targeted by the drug include shortness of breath, cough with sticky phlegm, fatigue, and other related signs [1]